Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Stuart M. Sprague

TitleClinical Professor
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 Jul 01; 34(7):1163-1170. PMID: 29846719.
      View in: PubMed
    2. Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 Oct; 96(4):1030-1036. PMID: 31377056.
      View in: PubMed
    3. Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 Jun; 30(6):1096-1108. PMID: 31085679.
      View in: PubMed
    4. Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293. PMID: 30878999.
      View in: PubMed
    5. Prasad PV, Li LP, Thacker JM, Li W, Hack B, Kohn O, Sprague SM. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. Am J Nephrol. 2019; 49(2):114-124. PMID: 30669143.
      View in: PubMed
    6. Altman AM, Sprague SM. Mineral and Bone Disease in Kidney Transplant Recipients. Curr Osteoporos Rep. 2018 12; 16(6):703-711. PMID: 30390201.
      View in: PubMed
    7. Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117. PMID: 30318163.
      View in: PubMed
    8. Sprague SM, Floege J. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148. PMID: 29985725.
      View in: PubMed
    9. Prasad PV, Li W, Raj DS, Carr J, Carr M, Thacker J, Li LP, Wang C, Sprague SM, Ix JH, Chonchol M, Block G, Cheung AK, Raphael K, Gassman J, Wolf M, Fried LF, Isakova T. Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD. Kidney Int Rep. 2018 Nov; 3(6):1467-1472. PMID: 30450473.
      View in: PubMed
    10. Dhillon-Jhattu S, Sprague SM. Should phosphate management be limited to the KDIGO/ KDOQI guidelines? Semin Dial. 2018 07; 31(4):377-381. PMID: 29671909.
      View in: PubMed
    11. Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491. PMID: 29656600.
      View in: PubMed
    12. Li LP, Thacker J, Li W, Tan H, Wang C, Kohn O, Sprague S, Prasad P. Consistency of Multiple Renal Functional MRI Measurements Over 18 Months. J Magn Reson Imaging. 2018 08; 48(2):514-521. PMID: 29517835.
      View in: PubMed
    13. Sprague S, Bhandari M, Heetveld MJ, Liew S, Scott T, Bzovsky S, Heels-Ansdell D, Zhou Q, Swiontkowski M, Schemitsch EH. Factors associated with health-related quality of life, hip function, and health utility after operative management of femoral neck fractures. Bone Joint J. 2018 03 01; 100-B(3):361-369. PMID: 29589490.
      View in: PubMed
    14. Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1918-1926. PMID: 28339993.
      View in: PubMed
    15. Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017 Aug 01; 32(8):1330-1338. PMID: 27342579.
      View in: PubMed
    16. Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C, Maddux FW, Kossmann RJ, Sprague SM. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data?. Clin Nephrol. 2017 Aug; 88(8):59-67. PMID: 28587714.
      View in: PubMed
    17. Sprague SM, Strugnell SA, Bishop CW. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017 09; 12(5):289-301. PMID: 30058895.
      View in: PubMed
    18. Alexander AJ, Jahangir D, Lazarus M, Sprague SM. Imaging in Chronic Kidney Disease-Metabolic Bone Disease. Semin Dial. 2017 07; 30(4):361-368. PMID: 28382631.
      View in: PubMed
    19. Santiago L, Menaa C, Arias M, Martin P, Jaime-Sánchez P, Metkar S, Comas L, Erill N, Gonzalez-Rumayor V, Esser E, Galvez EM, Raja S, Simon MM, Sprague SM, Gabay C, Martinez-Lostao L, Pardo J, Froelich CJ. Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis. Arthritis Rheumatol. 2017 Feb; 69(2):320-334. PMID: 27598995.
      View in: PubMed
    20. Sturgeon CM, Sprague S, Almond A, Cavalier E, Fraser WD, Algeciras-Schimnich A, Singh R, Souberbielle JC, Vesper HW. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH. Clin Chim Acta. 2017 Apr; 467:42-47. PMID: 27746210.
      View in: PubMed
    21. Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, Lee S, Petkovich PM, Bishop CW. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325. PMID: 27676085.
      View in: PubMed
    22. Li LP, Tan H, Thacker JM, Li W, Zhou Y, Kohn O, Sprague SM, Prasad PV. Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging. Kidney Int Rep. 2017 Jan; 2(1):36-43. PMID: 28868513.
      View in: PubMed
    23. Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, Rastogi A. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12. PMID: 27434393.
      View in: PubMed
    24. Nigwekar SU, Sprague SM. We Do Too Many Parathyroidectomies for Calciphylaxis. Semin Dial. 2016 07; 29(4):312-4. PMID: 27082830.
      View in: PubMed
    25. Thacker JM, Li LP, Li W, Zhou Y, Sprague SM, Prasad PV. Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective Analysis. Invest Radiol. 2015 Dec; 50(12):821-7. PMID: 26193455.
      View in: PubMed
    26. Prasad PV, Thacker J, Li LP, Haque M, Li W, Koenigs H, Zhou Y, Sprague SM. Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study. PLoS One. 2015; 10(10):e0139661. PMID: 26430736.
      View in: PubMed
    27. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D'Haese PC, Drüeke TB, Du H, Manley T, Rojas E, Moe SM. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66. PMID: 26321176.
      View in: PubMed
    28. Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol. 2015 Oct; 26(10):2328-39. PMID: 25967123.
      View in: PubMed
    29. Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40. PMID: 25904755.
      View in: PubMed
    30. Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30. PMID: 25873267.
      View in: PubMed
    31. Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70. PMID: 25736620.
      View in: PubMed
    32. Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015 Jun; 30(6):1037-46. PMID: 25691681.
      View in: PubMed
    33. Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45. PMID: 25572630.
      View in: PubMed
    34. Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 05; 9(9):1620-6. PMID: 24970869.
      View in: PubMed
    35. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep; 86(3):638-47. PMID: 24646861.
      View in: PubMed
    36. Zhang Y, Lapidos KA, Gal-Moscovici A, Sprague SM, Ameer GA. A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs. 2014 Jun; 38(6):474-83. PMID: 24206165.
      View in: PubMed
    37. Sprague SM. Painful skin ulcers in a hemodialysis patient. Clin J Am Soc Nephrol. 2014 Jan; 9(1):166-73. PMID: 24202137.
      View in: PubMed
    38. Ho LT, Sprague SM. Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013 Sep; 20(5):423-6. PMID: 23978548.
      View in: PubMed
    39. Sprague SM, Moe SM. Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013 Feb; 8(2):321. PMID: 23160258.
      View in: PubMed
    40. Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013 Feb; 61(2):310-25. PMID: 23102732.
      View in: PubMed
    41. Sprague SM, Moe SM. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013 Feb; 8(2):313-8. PMID: 23037984.
      View in: PubMed
    42. Lapidos KA, Sprague SM, Ameer GA. Impact of serum source and inflammatory cytokines on the isolation of endothelial colony-forming cells from peripheral blood. J Tissue Eng Regen Med. 2014 Sep; 8(9):747-56. PMID: 22888041.
      View in: PubMed
    43. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant. 2011 Nov; 26(11):3440-5. PMID: 22039013.
      View in: PubMed
    44. Sprague SM. Impact of CKD on coronary artery calcifications. Am J Kidney Dis. 2011 Oct; 58(4):503-5. PMID: 21944960.
      View in: PubMed
    45. Edwards BJ, Desai A, Tsai J, Du H, Edwards GR, Bunta AD, Hahr A, Abecassis M, Sprague S. Elevated incidence of fractures in solid-organ transplant recipients on glucocorticoid-sparing immunosuppressive regimens. J Osteoporos. 2011; 2011:591793. PMID: 21922049.
      View in: PubMed
    46. Sprague SM. Is bone mineral density measurement of any value in a dialysis patient? Semin Dial. 2011 Jul-Aug; 24(4):433-4. PMID: 21801230.
      View in: PubMed
    47. Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2010 Dec; 17(6):535-9. PMID: 21030840.
      View in: PubMed
    48. Chung EJ, Qiu H, Kodali P, Yang S, Sprague SM, Hwong J, Koh J, Ameer GA. Early tissue response to citric acid-based micro- and nanocomposites. J Biomed Mater Res A. 2011 Jan; 96(1):29-37. PMID: 20949482.
      View in: PubMed
    49. Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, Wang O, Turner SA, Sprague SM. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010 Sep; 42(7):2503-8. PMID: 20832532.
      View in: PubMed
    50. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010 Jul; 78(2):146-51. PMID: 20505658.
      View in: PubMed
    51. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May; 55(5):773-99. PMID: 20363541.
      View in: PubMed
    52. Park JC, Kovesdy CP, Duong U, Streja E, Rambod M, Nissenson AR, Sprague SM, Kalantar-Zadeh K. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int. 2010 Apr; 14(2):182-92. PMID: 20345388.
      View in: PubMed
    53. Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, Kopple JD, Kalantar-Zadeh K. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54. PMID: 20199875.
      View in: PubMed
    54. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8. PMID: 20133492.
      View in: PubMed
    55. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8. PMID: 19825330.
      View in: PubMed
    56. Sprague SM, Evenepoel P, Curzi MP, González MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76. PMID: 19696213.
      View in: PubMed
    57. Barnato S, Sprague SM. Advances in renal bone disease: osteoporosis and chronic kidney disease. Curr Rheumatol Rep. 2009 Jul; 11(3):185-90. PMID: 19604462.
      View in: PubMed
    58. Khosla N, Sprague SM. When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51. PMID: 19573002.
      View in: PubMed
    59. Huang M, Sprague SM. Bone disease in kidney transplant patients. Semin Nephrol. 2009 Mar; 29(2):166-73. PMID: 19371807.
      View in: PubMed
    60. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85. PMID: 19056618.
      View in: PubMed
    61. Gal-Moscovici A, Sprague SM. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S170-4. PMID: 18988703.
      View in: PubMed
    62. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008 Sep; 3(5):1437-45. PMID: 18579668.
      View in: PubMed
    63. Menaa C, Esser E, Sprague SM. Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008 Jun; 73(11):1275-81. PMID: 18368032.
      View in: PubMed
    64. Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27. PMID: 18238737.
      View in: PubMed
    65. Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res. 2007 Dec; 22 Suppl 2:V91-4. PMID: 18290730.
      View in: PubMed
    66. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007 Dec; 23(12):3167-75. PMID: 17991307.
      View in: PubMed
    67. Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K. Abnormal bone and mineral metabolism in kidney transplant patients--a review. Am J Nephrol. 2008; 28(2):246-53. PMID: 17989497.
      View in: PubMed
    68. Guo M, Cox B, Mahale S, Davis W, Carranza A, Hayes K, Sprague S, Jimenez D, Ding Y. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke. Neuroscience. 2008 Jan 24; 151(2):340-51. PMID: 18160227.
      View in: PubMed
    69. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106. PMID: 17914251.
      View in: PubMed
    70. Sprague SM. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2007 Oct; 72(7):895; author reply 895-6. PMID: 17882244.
      View in: PubMed
    71. Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial. 2007 Sep-Oct; 20(5):423-30. PMID: 17897249.
      View in: PubMed
    72. Schumock GT, Sprague SM. Clinical and economic burden of fractures in patients with renal osteodystrophy. Clin Nephrol. 2007 Apr; 67(4):201-8. PMID: 17474555.
      View in: PubMed
    73. Sprague SM. Renal function and risk of hip and vertebral fractures in older women: is it always osteoporosis? Arch Intern Med. 2007 Jan 22; 167(2):115-6. PMID: 17242310.
      View in: PubMed
    74. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43. PMID: 17215573.
      View in: PubMed
    75. Gal-Moscovici A, Sprague SM. Bone health in chronic kidney disease-mineral and bone disease. Adv Chronic Kidney Dis. 2007 Jan; 14(1):27-36. PMID: 17200041.
      View in: PubMed
    76. Gal-Moscovici A, Sprague SM, Hutchison AJ, Shah N, Piraino B, Cunningham J. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial. 2007 Jan-Feb; 20(1):24-32. PMID: 17244115.
      View in: PubMed
    77. Gal-Moscovici A, Sprague SM. Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan. Clin Drug Investig. 2007; 27(2):105-13. PMID: 17217315.
      View in: PubMed
    78. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun; 69(11):1945-53. PMID: 16641930.
      View in: PubMed
    79. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76. PMID: 16431255.
      View in: PubMed
    80. Zisman AL, Sprague SM. Bone disease after kidney transplantation. Adv Chronic Kidney Dis. 2006 Jan; 13(1):35-46. PMID: 16412969.
      View in: PubMed
    81. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005 Nov-Dec; 25(6):591-5. PMID: 16282676.
      View in: PubMed
    82. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93. PMID: 16030053.
      View in: PubMed
    83. Daniels CM, Woolverton EM, Sprague SM, Ameer GA. Assessment of the stability of an immunoadsorbent for the extracorporeal removal of Beta-2-microglobulin from blood. Blood Purif. 2005; 23(4):287-97. PMID: 15942167.
      View in: PubMed
    84. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27; 78(8):1233-6. PMID: 15502727.
      View in: PubMed
    85. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90. PMID: 15112179.
      View in: PubMed
    86. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004 May; 19(5):1174-81. PMID: 15004264.
      View in: PubMed
    87. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004 Mar; 43(3):566-71. PMID: 14981616.
      View in: PubMed
    88. Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol. 2004 Jan; 24(1):82-90. PMID: 14730514.
      View in: PubMed
    89. Dzido G, Sprague SM. Dialysis-related amyloidosis. Minerva Urol Nefrol. 2003 Jun; 55(2):121-9. PMID: 12847416.
      View in: PubMed
    90. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr; 63(4):1483-90. PMID: 12631365.
      View in: PubMed
    91. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54. PMID: 12472790.
      View in: PubMed
    92. Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002 Nov; 22(6):488-93. PMID: 12430093.
      View in: PubMed
    93. Moberly JB, Mujais S, Gehr T, Hamburger R, Sprague S, Kucharski A, Reynolds R, Ogrinc F, Martis L, Wolfson M. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl. 2002 Oct; (81):S23-33. PMID: 12230479.
      View in: PubMed
    94. Sprague SM, Ho LT. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol. 2002 Aug; 58(2):155-60. PMID: 12227689.
      View in: PubMed
    95. Kim G, Sprague SM. Use of vitamin D analogs in chronic renal failure. Adv Ren Replace Ther. 2002 Jul; 9(3):175-83. PMID: 12203199.
      View in: PubMed
    96. Ho LT, Sprague SM. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Semin Nephrol. 2002 May; 22(3):268-75. PMID: 12012312.
      View in: PubMed
    97. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6. PMID: 11689388.
      View in: PubMed
    98. Dhingra RK, Sprague SM, Ojo AO, Leavey SF. Posttransplant bone disease: a case illustrating dramatic improvements in bone density with vitamin D replacement therapy. Transplantation. 2001 Jun 27; 71(12):1856-9. PMID: 11455270.
      View in: PubMed
    99. Balint E, Sprague SM. Beta(2)-microglobulin and bone cell metabolism. Nephrol Dial Transplant. 2001 Jun; 16(6):1108-11. PMID: 11390706.
      View in: PubMed
    100. Tran M, Rutecki GW, Sprague SM. The pathogenesis of beta(2)-microglobulin-induced bone lesions in dialysis-related amyloidosis. Semin Dial. 2001 Mar-Apr; 14(2):131-3. PMID: 11264782.
      View in: PubMed
    101. Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. Bone. 2001 Jan; 28(1):21-8. PMID: 11165939.
      View in: PubMed
    102. Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis. 2000 Oct; 36(4):789-96. PMID: 11007682.
      View in: PubMed
    103. Sprague SM. Mechanism of transplantation-associated bone loss. Pediatr Nephrol. 2000 Jul; 14(7):650-3. PMID: 10912536.
      View in: PubMed
    104. Weiger TM, Holmqvist MH, Levitan IB, Clark FT, Sprague S, Huang WJ, Ge P, Wang C, Lawson D, Jurman ME, Glucksmann MA, Silos-Santiago I, DiStefano PS, Curtis R. A novel nervous system beta subunit that downregulates human large conductance calcium-dependent potassium channels. J Neurosci. 2000 May 15; 20(10):3563-70. PMID: 10804197.
      View in: PubMed
    105. Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial. 2000 May-Jun; 13(3):152-5. PMID: 10833774.
      View in: PubMed
    106. Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, Almaden Y, Felsenfeld AJ. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35. PMID: 10804023.
      View in: PubMed
    107. Balint E, Marshall CF, Sprague SM. Role of interleukin-6 in beta2-microglobulin-induced bone mineral dissolution. Kidney Int. 2000 Apr; 57(4):1599-607. PMID: 10760095.
      View in: PubMed
    108. Dranitzki-Elhalel M, Wald H, Popovtzer MM, Sprague SM. 1,25-Dihydroxyvitamin D3-induced calcium efflux from calvaria is mediated by protein kinase C. J Bone Miner Res. 1999 Nov; 14(11):1822-7. PMID: 10571681.
      View in: PubMed
    109. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999 Mar; 14(3):456-63. PMID: 10027911.
      View in: PubMed
    110. Whang K, Healy KE, Elenz DR, Nam EK, Tsai DC, Thomas CH, Nuber GW, Glorieux FH, Travers R, Sprague SM. Engineering bone regeneration with bioabsorbable scaffolds with novel microarchitecture. Tissue Eng. 1999 Feb; 5(1):35-51. PMID: 10207188.
      View in: PubMed
    111. Whang K, Tsai DC, Nam EK, Aitken M, Sprague SM, Patel PK, Healy KE. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res. 1998 Dec 15; 42(4):491-9. PMID: 9827671.
      View in: PubMed
    112. Chiu MY, Sprague SM, Bruce DS, Woodle ES, Thistlethwaite JR, Josephson MA. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol. 1998 Apr; 9(4):677-83. PMID: 9555671.
      View in: PubMed
    113. Sprague SM, Popovtzer MM, Dranitzki-Elhalel M, Wald H. Parathyroid hormone-induced calcium efflux from cultured bone is mediated by protein kinase C translocation. Am J Physiol. 1996 Dec; 271(6 Pt 2):F1139-46. PMID: 8997387.
      View in: PubMed
    114. Miyata T, Sprague SM. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Nephrol Dial Transplant. 1996; 11 Suppl 3:86-90. PMID: 8840320.
      View in: PubMed
    115. Miyata T, Kawai R, Taketomi S, Sprague SM. Possible involvement of advanced glycation end-products in bone resorption. Nephrol Dial Transplant. 1996; 11 Suppl 5:54-7. PMID: 9044308.
      View in: PubMed
    116. Bushinsky DA, Sprague SM, Hallegot P, Girod C, Chabala JM, Levi-Setti R. Effects of aluminum on bone surface ion composition. J Bone Miner Res. 1995 Dec; 10(12):1988-97. PMID: 8619380.
      View in: PubMed
    117. Moe SM, Hack BK, Cummings SA, Sprague SM. Role of IL-1 beta and prostaglandins in beta 2-microglobulin-induced bone mineral dissolution. Kidney Int. 1995 Feb; 47(2):587-91. PMID: 7723245.
      View in: PubMed
    118. Sprague SM, Popovtzer MM. Is beta 2-microglobulin a mediator of bone disease? Kidney Int. 1995 Jan; 47(1):1-6. PMID: 7731134.
      View in: PubMed
    119. Bartosh SM, Sprague SM, Nakagawa Y, Baron BW, Aronson AJ. Severe hypercalcemia following neonatal liver transplantation. Miner Electrolyte Metab. 1995; 21(6):428-30. PMID: 8592488.
      View in: PubMed
    120. Moe SM, Sprague SM. Uremic encephalopathy. Clin Nephrol. 1994 Oct; 42(4):251-6. PMID: 7834918.
      View in: PubMed
    121. Sprague SM, Krieger NS, Bushinsky DA. Greater inhibition of in vitro bone mineralization with metabolic than respiratory acidosis. Kidney Int. 1994 Oct; 46(4):1199-206. PMID: 7861717.
      View in: PubMed
    122. Hammes M, DeMory A, Sprague SM. Hypocalcemia in end-stage renal disease: a consequence of spontaneous parathyroid gland infarction. Am J Kidney Dis. 1994 Sep; 24(3):519-22. PMID: 8079980.
      View in: PubMed
    123. Moe SM, Yu BO, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis. 1993 Aug; 22(2):300-7. PMID: 8352257.
      View in: PubMed
    124. Sprague SM, Krieger NS, Bushinsky DA. Aluminum inhibits bone nodule formation and calcification in vitro. Am J Physiol. 1993 May; 264(5 Pt 2):F882-90. PMID: 8498542.
      View in: PubMed
    125. Moe SM, Sprague SM. Beta 2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae. Am J Physiol. 1992 Sep; 263(3 Pt 2):F540-5. PMID: 1415583.
      View in: PubMed
    126. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9. PMID: 1595701.
      View in: PubMed
    127. Spiegel DM, Sprague SM. Serum amyloid P component: a predictor of clinical beta 2-microglobulin amyloidosis. Am J Kidney Dis. 1992 May; 19(5):427-32. PMID: 1585929.
      View in: PubMed
    128. Murray JC, Tanner CM, Sprague SM. Aluminum neurotoxicity: a reevaluation. Clin Neuropharmacol. 1991 Apr; 14(2):179-85. PMID: 2015614.
      View in: PubMed
    129. Sprague SM, Bushinsky DA. Mechanism of aluminum-induced calcium efflux from cultured neonatal mouse calvariae. Am J Physiol. 1990 Mar; 258(3 Pt 2):F583-8. PMID: 2316667.
      View in: PubMed
    130. Corwin HL, Sprague SM, DeLaria GA, Norusis MJ. Acute renal failure associated with cardiac operations. A case-control study. J Thorac Cardiovasc Surg. 1989 Dec; 98(6):1107-12. PMID: 2586128.
      View in: PubMed
    131. Sprague SM, Corwin HL, Tanner CM, Wilson RS, Green BJ, Goetz CG. Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. Arch Intern Med. 1988 Oct; 148(10):2169-72. PMID: 3178374.
      View in: PubMed
    132. Warren GV, Sprague SM, Corwin HL. Sarcoidosis presenting as acute renal failure during pregnancy. Am J Kidney Dis. 1988 Aug; 12(2):161-3. PMID: 3400635.
      View in: PubMed
    133. Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med. 1986 Oct; 146(10):2063-4. PMID: 3767553.
      View in: PubMed
    134. Shore D, Sprague SM, Mayor GH, Moreno EC, Apostoles PS, Wyatt RJ. Aluminum-fluoride complexes: preclinical studies. J Environ Pathol Toxicol Oncol. 1985 Sep-Oct; 6(1):9-13. PMID: 4067838.
      View in: PubMed
    135. Commissaris RL, Cordon JJ, Sprague S, Keiser J, Mayor GH, Rech RH. Behavioral changes in rats after chronic aluminum and parathyroid hormone administration. Neurobehav Toxicol Teratol. 1982 May-Jun; 4(3):403-10. PMID: 7099360.
      View in: PubMed
    136. Mayor GH, Sprague SM, Sanchez TV. Determinants of tissue aluminum concentration. Am J Kidney Dis. 1981 Nov; 1(3):141-5. PMID: 7036718.
      View in: PubMed
    137. Mayor GH, Sprague SM, Hourani MR, Sanchez TV. Parathyroid hormone-mediated aluminum deposition and egress in the rat. Kidney Int. 1980 Jan; 17(1):40-4. PMID: 7374019.
      View in: PubMed
    138. McCormack KM, Ottosen LD, Sanger VL, Sprague S, Mayor GH, Hook JB. Effect of prenatal administration of aluminum and parathyroid hormone on fetal development in the rat. Proc Soc Exp Biol Med. 1979 May; 161(1):74-7. PMID: 441074.
      View in: PubMed
    139. Mayor GH, Keiser JA, Sanchez TV, Sprague SM, Hook JB. Factors affecting tissue aluminum concentration. J Dial. 1978; 2(5-6):471-81. PMID: 374433.
      View in: PubMed
    Sprague's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _